Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation

Table 5 Comparative life quality evaluation

Quality of life	Control group (n = 60)	Research group (n = 64)	t	P value
Material conditions (points)
Pre-treatment	64.05 ± 6.02	64.19 ± 7.51	0.114	0.909
Post-treatment	82.72 ± 7.06c	86.03 ± 6.32c	2.754	0.007
Mental well-being (points)
Pre-treatment	60.98 ± 5.91	62.80 ± 7.29	1.521	0.131
Post-treatment	82.87 ± 6.53c	88.66 ± 6.54c	4.930	< 0.001
Bodily function (points)
Pre-treatment	63.23 ± 5.00	64.27 ± 6.03	1.042	0.300
Post-treatment	84.57 ± 5.32c	89.33 ± 6.27c	4.544	< 0.001
Societal role (points)
Pre-treatment	66.25 ± 6.63	64.52 ± 6.38	1.481	0.141
Post-treatment	83.13 ± 6.77c	88.25 ± 5.66c	4.580	< 0.001

^cP < 0.001 vs pre-treatment within the same group.